

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Adherium Limited
ABN	24 605 352 510

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	George Baran
Date of last notice	19 May 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Issue of securities to the Director's nominee Trudell Medical Limited in lieu of cash payment of Director Fees. The Director has a 33.33% beneficial interest in Trudell Medical Limited.
Date of change	26 November 2021
No. of securities held prior to change	(a) Indirect interest in 422,697,512 fully paid ordinary shares (b) Indirect interest in 10,485,950 options over fully paid ordinary shares, each with a \$0.0219 exercise price and 29 January 2027 expiry date
Class	Ordinary fully paid shares
Number acquired	382,760 ordinary fully paid shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Issue in lieu of cash payment of Director fees of \$6,720 for the period 13 May 2021 to 30 June 2021

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	(a) Indirect interest in 423,080,272 fully paid ordinary shares (b) Indirect interest in 10,485,950 options over fully paid ordinary shares, each with a \$0.0219 exercise price and 29 January 2027 expiry date
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue in lieu of cash payment of Director Fees amounting to \$6,720 with the approval of shareholders under listing rule 10.11

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.